| Results From The First And Largest Collaborative Study Confirm Role Of Enbrel® In Psoriatic Arthritis |
| New data presented today at the 'Gene to Clinic' meeting taking place at the Royal College of Physicians in London, England, reinforce Enbrel's ability to clear skin in patients with psoriatic arthritis, an inflammatory and progressive disease associated with psoriasis.
12/04/2008
|
| Researchers From La Jolla Institute And Albany Medical College Identify Cell Group Key To Lyme Disease Arthritis |
| A research team led by the La Jolla Institute for Allergy & Immunology and Albany Medical College has illuminated the important role of natural killer (NK) T cells in Lyme disease, demonstrating that the once little understood white blood cells are central to clearing the bacterial infection and reducing the intensity and duration of arthritis associated with Lyme disease.
12/04/2008
|
| Better Management More Important Than New Drugs For Arthritis |
| Although there has been an increase in the number of new arthritis treatments in recent years, the best results will come from more effective use of the drugs we have. Research published in BioMed Central's open access journal Arthritis Research and Therapy investigates the effectiveness of available arthritis drugs and concludes that better management is the most important factor.
11/29/2008
|
| Key US Patent Granted On Antibodies Against GM-CSF To Treat Inflammatory Disorders (Rheumatoid Arthritis) |
| MorphoSys AG (FSE: MOR; Prime Standard Segment, TecDAX) and the University of Melbourne announced today that the U.S. Patent & Trademark Office (USPTO) has confirmed that it will issue U.S. Patent No. 7,455,836, covering key uses of antibodies against GM-CSF. The patent stems from a provisional patent application filed in the USPTO in 2000 by the University of Melbourne.
11/25/2008
|
| Arthritis Advisory Committee Recommends FDA Approval Of Febuxostat For The Treatment Of Hyperuricemia In Patients With Gout |
| Takeda Pharmaceutical Company Limited and its wholly-owned subsidiary, Takeda Global Research & Development Center, Inc., U.S., announced today that the Arthritis Advisory Committee of the U.S. Food and Drug Administration (FDA) recommended that the FDA approve febuxostat for the treatment of hyperuricemia in patients with gout. The vote was 12 to zero in favor of approval, with one panel member abstaining.
11/25/2008
|
| NICE Admits Previous Guidance Around Sequential Use Of Anti-TNF Therapies In Rheumatoid Arthritis Unfair |
| The National Institute of Health and Clinical Excellence (NICE) has today published findings of its appeal panel around the use of adalimumab, etanercept and infliximab for the treatment of rheumatoid arthritis (RA) after failure of a previous TNF-α inhibitor (sequential use), deciding their previous guidance had been 'unfair' and 'perverse'1.
11/24/2008
|
| RoActemra Receives Positive Opinion In Europe For The Treatment Of Rheumatoid Arthritis |
| Roche announced that the European Committee on Human Medicinal Products (CHMP) has given a positive recommendation for RoActemra (tocilizumab, known as Actemra outside of the EU), in combination with methotrexate (MTX), for the treatment of adult patients with moderate to severe rheumatoid arthri
11/22/2008
|
| Musculoskeletal Center Wins $2.2 Million For Drug Safety |
| The University of Alabama at Birmingham (UAB) Center for Education and Research on Therapeutics (CERTs) has won a $2.2 million federal grant to study the risks and benefits of a newer class of medicines called biologics. These are genetically engineered therapies that target the immune system of patients who have rheumatoid arthritis, Crohn's disease, psoriasis and other autoimmune disorders.
11/19/2008
|
| Grape Powder Alleviates Joint Inflammation - Constituents In Grapes Have Antihyperalgesic Effects In A Rat Model Of Joint Inflammation |
| Johns Hopkins Researchers at Neuroscience 2008 - Table grapes are high in flavonoids, which are thought to have strong antioxidant and anti-inflammatory properties. Now, researchers at the Johns Hopkins University School of Medicine have shown that powdered grapes appear to reduce pain and inflammation in a rat model of arthritis, where rats knees are inflamed using a chemical injection.
11/18/2008
|
| Rheumatoid Arthritis - Cimzia(R) Studies Show Significant Clinical Benefits For Mono- And Combination Therapy |
| UCB today announced the results of two phase III studies, published in the Annals of the Rheumatic Diseases Online, showing Cimzia® (certolizumab pegol), the only PEGylated anti-TNFalpha (Tumour Necrosis Factor alpha), provided significant clinical benefits as monotherapy, and in combination with methotrexate, in adults with active rheumatoid arthritis (RA).
11/18/2008
|
| FDA Clears The DPL (Deep Penetrating Light) Therapy System For Over-the-Counter - Home Use |
| LED Technologies, LLC announced today that the U.S. Food and Drug Administration (FDA) cleared their DPLâ„¢ Therapy System for the relaxation of muscles and relief of muscle spasms, temporary relief of minor muscle and joint aches, pains and stiffness; temporary relief of minor pain and stiffness associated with arthritis; and to temporarily increase local blood circulation.
11/18/2008
|
| New One-Stop Diabetic Rheumatology Clinic Is First In UK |
| Diabetes Mellitus is one of the most common chronic disorders in the population, affecting some 2 million people in the UK. Patients with diabetes (both Type 1 and 2) suffer an array of rheumatic complaints which are wide-ranging in nature and are often complex in management.
11/16/2008
|
| New Data Points To Long Lasting Beneficial Effects Of CEL-SCI's Rheumatoid Arthritis Vaccine |
| CEL-SCI Corporation (NYSE: CVM) announced the presentation of new rheumatoid arthritis data at the 6th annual GTCbio Vaccine Conference in Vienna, Va. The data, presented by Dr. Daniel Zimmerman, Senior Vice President of Research, Cellular Immunology of CEL-SCI, indicate that CEL-SCI's rheumatoid arthritis treatment vaccine CEL-2000 prevents or retards the permanent tissue damage caused by rheumatoid arthritis.
11/15/2008
|
| Arthritis - MorphoSys Publishes Preclinical Data From MOR103 Program |
| MorphoSys AG (FSE: MOR; Prime Standard Segment, TecDAX) announced today the publication of preclinical data from its most advanced proprietary drug development program MOR103, a fully human HuCAL antibody directed against GM-CSF.
11/13/2008
|
| Actelion's First-in-class Selective S1P1 Receptor Agonist To Enter Phase II Clinical Development |
| Actelion Ltd (SWX: ATLN) announced that Actelion and Roche have jointly agreed that preclinical and clinical data support progressing Actelion's S1P1 receptor agonist into Phase II clinical development. An update will be presented at Actelion Day 2009, an event held at Actelion's headquarters in Allschwil on 19 February 2009. This event will be a combination of Actelion's annual Media and Analyst Conference and its Research and Development Day.
11/13/2008
|
